A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. 2004

Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
Research Foundation Itsuu Laboratory, Tokyo, Japan. kshudo@itsuu.or.jp

Memory deficit in rats treated with scopolamine was rescued by several synthetic retinoids, RAR-ligands (Am80, Am555S, Tp80) and an RXR-ligand (HX630). These results may have implications for the treatment of Alzheimer's disease, age-related dementia, Parkinson's disease, and other neurological disorders.

UI MeSH Term Description Entries
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001362 Avoidance Learning A response to a cue that is instrumental in avoiding a noxious experience. Aversion Behavior,Aversion Learning,Aversive Behavior,Aversive Learning,Avoidance Behavior,Aversion Behaviors,Aversive Behaviors,Avoidance Behaviors,Behavior, Aversion,Behavior, Aversive,Behavior, Avoidance,Behaviors, Aversion,Behaviors, Aversive,Behaviors, Avoidance,Learning, Aversion,Learning, Aversive,Learning, Avoidance
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D001565 Benzoates Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure. Benzoate,Benzoic Acids,Acids, Benzoic
D012176 Retinoids A group of tetraterpenes, with four terpene units joined head-to-tail. Biologically active members of this class are used clinically in the treatment of severe cystic ACNE; PSORIASIS; and other disorders of keratinization. Retinoid
D012601 Scopolamine An alkaloid from SOLANACEAE, especially DATURA and SCOPOLIA. Scopolamine and its quaternary derivatives act as antimuscarinics like ATROPINE, but may have more central nervous system effects. Its many uses include an anesthetic premedication, the treatment of URINARY INCONTINENCE and MOTION SICKNESS, an antispasmodic, and a mydriatic and cycloplegic. Hyoscine,Scopolamine Hydrobromide,Boro-Scopol,Isopto Hyoscine,Kwells,Scoburen,Scopace,Scopoderm TTS,Scopolamine Cooper,Transderm Scop,Transderm-V,Travacalm HO,Vorigeno,Boro Scopol,Transderm V

Related Publications

Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
June 2005, Leukemia,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
November 2008, Cancer science,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
February 2011, Cancer science,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
July 2009, Biological & pharmaceutical bulletin,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
November 1988, Behavioral and neural biology,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
January 2018, European journal of pharmacology,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
November 2007, European journal of pharmacology,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
December 2010, Behavioural pharmacology,
Koichi Shudo, and Hiroyuki Kagechika, and Noriyuki Yamazaki, and Masaharu Igarashi, and Chiaki Tateda
June 2009, Cancer science,
Copied contents to your clipboard!